Skip to main content
. Author manuscript; available in PMC: 2014 Jan 2.
Published in final edited form as: Cancer Res. 2008 May 1;68(9):10.1158/0008-5472.CAN-08-0132. doi: 10.1158/0008-5472.CAN-08-0132

Figure 4.

Figure 4

Met is constitutively tyrosine phosphorylated in SUM229 cells and regulates c-Src phosphorylation and activity. A, using a phospho-proteomic array (R&D Systems), lysates from gefitinib-treated SUM149 and SUM229 breast cancer cells were exposed to membranes spotted with antibodies representing 42 different receptor tyrosine kinases. The unbound lysate was washed away and phospho-tyrosine specific antibodies linked to HRP were added to detect receptors that are tyrosine phosphorylated. White boxes, differences seen in the tyrosine phosphorylation of Met in the cells that proliferate in the presence of EGFR TKIs compared with those that do not. B, lysates from SUM149 or SUM229 cells were prepared and separated by SDS-PAGE followed by immunoblotting using phospho-specific Met antibodies. C, SUM229 cells were either untreated or treated with 0.5 µmol/L gefitinib (E), 1.0 µmol/L SU11274 (M), or the combination (E+M) for 30 min. Lysates were prepared and separated by SDS-PAGE. Membranes were immunoblotted with pY845-EGFR or pY416 antibodies.